Caleb A Lareau, Yajie Yin, Katie Maurer, Katalin D Sandor, Bence Daniel, Garima Yagnik, José Peña, Jeremy Chase Crawford, Anne M Spanjaart, Jacob C Gutierrez, Nicholas J Haradhvala, Janice M Riberdy, Tsion Abay, Robert R Stickels, Jeffrey M Verboon, Vincent Liu, Frank A Buquicchio, Fangyi Wang, Jackson Southard, Ren Song, Wenjing Li, Aastha Shrestha, Laxmi Parida, Gad Getz, Marcela V Maus, Shuqiang Li, Alison Moore, Zachary J Roberts, Leif S Ludwig, Aimee C Talleur, Paul G Thomas, Houman Dehghani, Thomas Pertel, Anshul Kundaje, Stephen Gottschalk, Theodore L Roth, Marie J Kersten, Catherine J Wu, Robbie G Majzner, Ansuman T Satpathy
Cell therapies have yielded durable clinical benefits for patients with cancer, but the risks associated with the development of therapies from manipulated human cells are understudied. For example, we lack a comprehensive understanding of the mechanisms of toxicities observed in patients receiving T cell therapies, including recent reports of encephalitis caused by reactivation of human herpesvirus 6 (HHV-6)1 . Here, through petabase-scale viral genomics mining, we examine the landscape of human latent viral reactivation and demonstrate that HHV-6B can become reactivated in cultures of human CD4+ T cells...
November 2023: Nature